Skip to main content

Market Overview

Goldman Recommends Selling Puma Biotech, Clovis Oncology; Cites Company-Specific, Competitive Risks

Goldman Recommends Selling Puma Biotech, Clovis Oncology; Cites Company-Specific, Competitive Risks

Belying the popular notion that oncology biotechs are lucrative investment options,Goldman Sachs is taking a bearish stance on Puma Biotechnology Inc (NASDAQ: PBYI) and Clovis Oncology Inc (NASDAQ: CLVS).

The Analyst

Analyst Paul Choi downgraded Puma from Neutral to Sell and reduced the price target from $24 to $8.

The analyst reiterated a Sell rating on Clovis shares and lowered the price target from $13 to $3.

The Thesis

Smid-cap oncology biotech stocks, especially those with exposure to precision oncology and targeted therapy, have nearly doubled year-to-date, Choi said in a Tuesday note. (See his track record here.)

Yet Puma and Clovis have meaningfully underperformed, with investor expectations having worsened further, the analyst said.

Choi said he sees potential for further downside due to underappreciated company-specific and competitive risks.

See also: BioNTech IPO: What You Need To Know

Puma Faces Headline Risk From Rival Breast Cancer Drug

Competitive data from Seattle Genetics, Inc. (NASDAQ: SGEN)'s tucatinib at the end of 2019 creates a challenging setup for Puma's Nerlyx, for which the next potential driver is likely to be in HER2+ metastatic breast cancer, the analyst said. 

"We believe that even if tucatinib is not differentiated on efficacy, it may garner more market share on greater tolerability based on mCRC data shown at ESMO." 

Goldman Sachs reduced its 2025 sales estimate for Puma by 25% on a lower expected uptake in the metastatic setting and slower international adoption of Nerlynx.

Diminished Top-Line Outlook, Investment Seen As Overhangs On Clovis

With respect to Clovis, Choi projects risk to longer-term consensus estimates that have baked in meaningful growth driven from Rubraca's use in prostate cancer and a frontline/combo use with PD-1s.

Following AstraZeneca plc (NYSE: AZN)- Merck & Co., Inc. (NYSE: MRK)'s Lynparza PROfound prostate and PAOLA-1/PRIMA first-line maintenance ovarian data, Goldman reduced its peak Rubraca sales estimate by 25% on lower expected share in prostate and ovarian.

"Given the diminished topline outlook and continuing investment in rucaparib label expansion, we see the high cash burn and convertible debt burden continuing to be overhangs on the stock," Choi said.

Price Action

Puma shares were tumbling 17.43% to $8.32 at the time of publication, while Clovis shares were down 9.14% at $3.27.

Latest Ratings for CLVS

Nov 2020SVB LeerinkMaintainsUnderperform
Nov 2020HC Wainwright & Co.MaintainsBuy
May 2020HC Wainwright & Co.ReiteratesBuy

View More Analyst Ratings for CLVS
View the Latest Analyst Ratings


Related Articles (CLVS + PBYI)

View Comments and Join the Discussion!

Posted-In: Analyst Color Biotech Downgrades Price Target Reiteration Top Stories Analyst Ratings Trading Ideas Best of Benzinga

Latest Ratings

NIUDaiwa CapitalInitiates Coverage On41.5
QMCONorthland Capital MarketsInitiates Coverage On12.0
IBKRJefferiesInitiates Coverage On89.0
MRETFTD SecuritiesDowngrades18.5
SWKSGoldman SachsDowngrades135.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at